Compare Abbott Laboratories (ABT) vs Deckers Outdoor Corp (DECK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Deckers Outdoor Corp — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Deckers Outdoor Corp trades at $102.61 (market cap $14.73B). The key difference: Abbott Laboratories is far larger — about 11.3× Deckers Outdoor Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals.
| ABT | DECK | |
|---|---|---|
Market Cap | $166.94B | $14.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $123.91 |
52-Week Low | $82.57 | $79.54 |
Enterprise Value | $193.69B | $13.20B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Deckers Outdoor Corp (DECK) trades at $106.08, up 1.33% today, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.99B in 2025, with net income reaching $966M and a robust ROE of 40.86%. Recent quarters show consistent earnings beats, and analyst consensus targets $121.50. The stock benefits from international expansion of UGG and HOKA brands, as highlighted by Zacks Investment Research on 2026-07-01.
The outlook for DECK is positive, supported by earnings momentum and global growth initiatives, but risks include competitive pressures and market volatility. With a P/E of 15.05, the stock appears reasonably valued, offering potential upside to the consensus target. Investors should weigh strong profitability against sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →
